Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Desiree Van Oorschot"'
Autor:
Enrique Chacon-Cruz, Erika Zoe Lopatynsky-Reyes, Gloria Huerta-Garcia, Maria Yolanda Cervantes-Apolinar, Adriana Guzman-Holst, Desiree Van Oorschot
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Invasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition mainly affecting children and adolescents. Active surveillance between 2005 and 2016 at Tijuana General Hospital, Mexico, indicated that the incidence of
Externí odkaz:
https://doaj.org/article/8d5da6f3ec4545c5ada670f5682cad1f
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 26, Iss , Pp 102411- (2022)
Introdução: O herpes-zoster (HZ) manifesta-se normalmente em idosos ou indivíduos imunocomprometidos a partir da reativação do vírus varicela zoster latente. Sem vacinação, até 30% das pessoas estão sob o risco de desenvolver HZ durante a v
Externí odkaz:
https://doaj.org/article/3d1b0d40f9b9436299afd0f849606129
Autor:
Desmond Curran, Brandon J. Patterson, Desiree Van Oorschot, Philip O. Buck, Justin Carrico, Katherine A. Hicks, Bruce Lee, Barbara P. Yawn
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 765-771 (2019)
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committe
Externí odkaz:
https://doaj.org/article/e32a74a9e71e4cde9b0d2cb2e3ab1819
Autor:
Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, Desmond Curran, Desiree Van Oorschot, Benjamin Bracke, Daisuke Watanabe
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 2, Pp 281-297 (2019)
Abstract Introduction The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objecti
Externí odkaz:
https://doaj.org/article/3958e43289bb4c568abb57c6bcb319ea
Autor:
John Paget, Helen Aangenend, Malte Kühn, Jeannine Hautvast, Desiree van Oorschot, Alphons Olde Loohuis, Koos van der Velden, Alexander W Friedrich, Andreas Voss, Robin Köck
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0139589 (2015)
ObjectivesMRSA poses a considerable public health threat to the community. The objectives of this study were to assess the prevalence of MRSA carriage and determine factors that were associated with MRSA carriage among outpatients who had used antibi
Externí odkaz:
https://doaj.org/article/67a47b2d54fc4692bc1073dcf416f667
Autor:
Jeffrey J. Stoddard, Philip O. Buck, Desmond Curran, William L. Herring, Desiree Van Oorschot, Yuanhui Zhang, Justin Carrico, Brandon J. Patterson
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 3, Pp 596-604 (2021)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Objective To investigate the potential public health impact of adult herpes zoster (HZ) vaccination with the adjuvanted recombinant zoster vaccine (RZV) in the United States in the first 15 years after launch. Methods We used a publicly available mod
Autor:
William L. Herring, Lina S. Sy, Bradley Ackerson, Desiree Van Oorschot, Yuanhui Zhang, Hung-Fu Tseng, Justin Carrico, Brandon J. Patterson, Desmond Curran, Katia Bruxvoort
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1567-1575
In 2017, the FDA approved the adjuvanted recombinant zoster vaccine (RZV) for the prevention of herpes zoster (HZ) in immunocompetent adults aged 50 years and older. RZV joined zoster vaccine live (ZVL) as U.S.-marketed vaccines against HZ. The Advis
Autor:
Michael L. Ganz, Michael Stokes, Ashleigh McGirr, Robyn Widenmaier, Lijoy Varghese, Desmond Curran, Hyosung Jung, Desiree Van Oorschot
Publikováno v:
Applied Health Economics and Health Policy
Objectives In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvant
Autor:
Katherine Hicks, Desiree Van Oorschot, Desmond Curran, Brandon J. Patterson, Justin Carrico, Barbara P. Yawn, Bruce Y. Lee, Philip O. Buck
Publikováno v:
Human Vaccines & Immunotherapeutics
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committe
Autor:
John Diaz-Decaro, Barbara P. Yawn, Desmond Curran, H Vroling, Desiree Van Oorschot, Eveline M Bunge
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
We conducted a systematic review to characterize the incidence rate of herpes zoster (HZ) in the general population, specifically in individuals ≥50 years of age. A total of 69 publications were included in the review. We found a cumulative inciden